Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112).

Sotaro MotoiMai UesugiTakashi ObaraKatsuhiro MoriyaYoshihisa AritaHideaki OgasawaraMotohiro SoejimaToshio ImaiTetsu Kawano

Published in: International journal of molecular sciences (2021)

APOA4 was identified as a soluble PD marker of rh-HGF with c-Met dependency. It should be worthwhile to clinically validate its utility through clinical trials with healthy subjects and ALF patients.

Keyphrases

growth factor
clinical trial
recombinant human
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
tyrosine kinase
liver injury
phase ii
open label
drug induced